EIKN (Eikon Therapeutics) Accounts Payable: $6.56 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EIKN Eikon Therapeutics Inc EIKN
12 GF Score
Price $10.93
View Full Analysis

What is Eikon Therapeutics Accounts Payable?

Eikon Therapeutics EIKN -3.78% 12 Accounts Payable is $6.56 Mil as of Jun. 2026. GuruFocus rates EIKN with a GF Score™ of 12/100.

Eikon Therapeutics's Accounts Payable for the quarter that ended in Jun. 2026 was $6.56 Mil.

Eikon Therapeutics's quarterly Accounts Payable increased from Dec. 2025 ($0.68 Mil) to Mar. 2026 ($6.01 Mil) and increased from Mar. 2026 ($6.01 Mil) to Jun. 2026 ($6.56 Mil).

Eikon Therapeutics's annual Accounts Payable increased from Dec. 2023 ($2.19 Mil) to Dec. 2024 ($17.58 Mil) but then declined from Dec. 2024 ($17.58 Mil) to Dec. 2025 ($0.68 Mil).

Eikon Therapeutics Accounts Payable Related Terms

Eikon Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Eikon Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics Accounts Payable Chart

Eikon Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Accounts Payable
2.19 17.58 0.68

Eikon Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial 0.00 4.28 0.68 6.01 6.56
EIKN
12GF Score
Eikon Therapeutics Inc EIKN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eikon Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $6.56 Mil mean?
Eikon Therapeutics (EIKN) has a Accounts Payable of $6.56 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Eikon Therapeutics and its competitors.
Is Eikon Therapeutics' Accounts Payable too high?
Eikon Therapeutics' current Accounts Payable is $6.56 Mil. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' Accounts Payable compare to SPRY and ARVN?
Eikon Therapeutics' Accounts Payable of $6.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Eikon Therapeutics and its competitors. Eikon Therapeutics's current Accounts Payable is $6.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current Accounts Payable of $6.56 Mil. The current Accounts Payable is $6.56 Mil. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current Accounts Payable is $6.56 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eikon Therapeutics Business Description

Address 230 Harriet Tubman Way, Millbrae, CA, USA, 94030
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score

Get the complete analysis for EIKN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.93
Price